Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

Sex differences in the temperature dependence of kidney stone presentations: a population-based aggregated case-crossover study.

Vicedo-Cabrera AM, Goldfarb DS, Kopp RE, Song L, Tasian GE.

Urolithiasis. 2019 Mar 21. doi: 10.1007/s00240-019-01129-x. [Epub ahead of print]

PMID:
30900001
2.

Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts.

Beara-Lasic L, Cogal A, Mara K, Enders F, Mehta RA, Haskic Z, Furth SL, Trachtman H, Scheinman SJ, Milliner DS, Goldfarb DS, Harris PC, Lieske JC; investigators of the Rare Kidney Stone Consortium.

Pediatr Nephrol. 2019 Mar 10. doi: 10.1007/s00467-019-04210-0. [Epub ahead of print]

PMID:
30852663
3.

Blood volume analysis as a guide for dry weight determination in chronic hemodialysis patients: a crossover study.

Malha L, Fattah H, Modersitzki F, Goldfarb DS.

BMC Nephrol. 2019 Feb 11;20(1):47. doi: 10.1186/s12882-019-1211-7.

4.

Editorial: Controversies in kidney stones and other chronic kidney disease topics.

Goldfarb DS.

Curr Opin Nephrol Hypertens. 2019 Mar;28(2):128-129. doi: 10.1097/MNH.0000000000000485. No abstract available.

PMID:
30585853
5.

Differences in national and international guidelines regarding use of kidney stone formers as living kidney donors.

Tatapudi VS, Goldfarb DS.

Curr Opin Nephrol Hypertens. 2019 Mar;28(2):140-147. doi: 10.1097/MNH.0000000000000480.

PMID:
30531468
6.

Urine proteomic profiling in patients with nephrolithiasis and cystinuria.

Kovacevic L, Caruso JA, Lu H, Kovacevic N, Lakshmanan Y, Carruthers NJ, Goldfarb DS.

Int Urol Nephrol. 2018 Dec 5. doi: 10.1007/s11255-018-2044-1. [Epub ahead of print]

PMID:
30519981
7.

Cystinuria: genetic aspects, mouse models, and a new approach to therapy.

Sahota A, Tischfield JA, Goldfarb DS, Ward MD, Hu L.

Urolithiasis. 2019 Feb;47(1):57-66. doi: 10.1007/s00240-018-1101-7. Epub 2018 Dec 4. Review.

PMID:
30515543
8.

Empiric therapy for kidney stones.

Goldfarb DS.

Urolithiasis. 2019 Feb;47(1):107-113. doi: 10.1007/s00240-018-1090-6. Epub 2018 Nov 26. Review.

PMID:
30478476
9.

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.

Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB.

Rheumatology (Oxford). 2019 Jan 1;58(1):61-69. doi: 10.1093/rheumatology/key245.

10.

Managing protein-energy wasting in hemodialysis patients: A comparison of animal- and plant-based protein foods.

St-Jules DE, Goldfarb DS, Popp CJ, Pompeii ML, Liebman SE.

Semin Dial. 2019 Jan;32(1):41-46. doi: 10.1111/sdi.12737. Epub 2018 Jul 15. Review.

PMID:
30009545
11.

Assessment and misassessment of potassium, phosphorus, and protein in the hemodialysis diet.

St-Jules DE, Goldfarb DS, Pompeii ML, Liebman SE, Sherman RA.

Semin Dial. 2018 Sep;31(5):479-486. doi: 10.1111/sdi.12713. Epub 2018 May 29. Review.

PMID:
29813179
12.

Oral Antibiotic Exposure and Kidney Stone Disease.

Tasian GE, Jemielita T, Goldfarb DS, Copelovitch L, Gerber JS, Wu Q, Denburg MR.

J Am Soc Nephrol. 2018 Jun;29(6):1731-1740. doi: 10.1681/ASN.2017111213. Epub 2018 May 10.

PMID:
29748329
13.

Chronic pain in medullary sponge kidney: a rare and never described clinical presentation.

Gambaro G, Goldfarb DS, Baccaro R, Hirsch J, Topilow N, D'Alonzo S, Gambassi G, Ferraro PM.

J Nephrol. 2018 Aug;31(4):537-542. doi: 10.1007/s40620-018-0480-8. Epub 2018 Feb 21.

PMID:
29468561
14.

Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia.

Liu Y, Goldfarb DS, El-Achkar TM, Lieske JC, Wu XR.

Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1062-F1076. doi: 10.1152/ajprenal.00233.2017. Epub 2018 Jan 10.

PMID:
29357410
15.

Assessment of the combination of temperature and relative humidity on kidney stone presentations.

Ross ME, Vicedo-Cabrera AM, Kopp RE, Song L, Goldfarb DS, Pulido J, Warner S, Furth SL, Tasian GE.

Environ Res. 2018 Apr;162:97-105. doi: 10.1016/j.envres.2017.12.020. Epub 2017 Dec 28.

PMID:
29289860
16.

Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with Adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial.

Edvardsson VO, Runolfsdottir HL, Thorsteinsdottir UA, Sch Agustsdottir IM, Oddsdottir GS, Eiriksson F, Goldfarb DS, Thorsteinsdottir M, Palsson R.

Eur J Intern Med. 2018 Feb;48:75-79. doi: 10.1016/j.ejim.2017.10.007. Epub 2017 Dec 12.

17.

Case Study - Case Studies in Cystinuria.

Goldfarb DS, Grasso M.

Urol Nurs. 2017 Mar-Apr;37(2):90-3.

18.

Early Recognition and Management of Rare Kidney Stone Disorders.

Goldstein B, Goldfarb DS.

Urol Nurs. 2017 Mar-Apr;37(2):81-9, 102.

19.

Meeting the Needs of the Complex Older Adult Patient with Urinary Retention: A Case Study.

Goldstein B, Goldfarb DS.

Urol Nurs. 2017 Mar-Apr;37(2):75-80.

PMID:
29240371
20.

Personalized Intervention in Monogenic Stone Formers.

Policastro LJ, Saggi SJ, Goldfarb DS, Weiss JP.

J Urol. 2018 Mar;199(3):623-632. doi: 10.1016/j.juro.2017.09.143. Epub 2017 Oct 20. Review.

21.

The Healthy Hearts and Kidneys (HHK) study: Design of a 2×2 RCT of technology-supported self-monitoring and social cognitive theory-based counseling to engage overweight people with diabetes and chronic kidney disease in multiple lifestyle changes.

Sevick MA, Woolf K, Mattoo A, Katz SD, Li H, St-Jules DE, Jagannathan R, Hu L, Pompeii ML, Ganguzza L, Li Z, Sierra A, Williams SK, Goldfarb DS.

Contemp Clin Trials. 2018 Jan;64:265-273. doi: 10.1016/j.cct.2017.08.020. Epub 2017 Sep 1.

22.

Refining Diagnostic Approaches in Nephrolithiasis: Incomplete Distal Renal Tubular Acidosis.

Goldfarb DS.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1380-1382. doi: 10.2215/CJN.07160717. Epub 2017 Aug 3. No abstract available.

23.

Phosphate Additive Avoidance in Chronic Kidney Disease.

St-Jules DE, Goldfarb DS, Pompeii ML, Sevick MA.

Diabetes Spectr. 2017 May;30(2):101-106. doi: 10.2337/ds16-0048.

24.

Opioid Overuse or NSAID Underuse? A Response to the Pain Guide.

Hiremath S, Goldfarb DS, Juurlink DN.

Am J Kidney Dis. 2017 Jun;69(6):865. doi: 10.1053/j.ajkd.2017.02.375. Epub 2017 Apr 25. No abstract available.

PMID:
28454686
25.

Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease.

Kalantar-Zadeh K, Crowley ST, Beddhu S, Chen JLT, Daugirdas JT, Goldfarb DS, Jin A, Kovesdy CP, Leehey DJ, Moradi H, Navaneethan SD, Norris KC, Obi Y, O'Hare A, Shafi T, Streja E, Unruh ML, Vachharajani TJ, Weisbord S, Rhee CM.

Semin Dial. 2017 May;30(3):251-261. doi: 10.1111/sdi.12601. Epub 2017 Apr 18. Review.

26.

Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in Saccharomyces cerevisiae.

Tombline G, Millen JI, Polevoda B, Rapaport M, Baxter B, Van Meter M, Gilbertson M, Madrey J, Piazza GA, Rasmussen L, Wennerberg K, White EL, Nitiss JL, Goldfarb DS.

Aging (Albany NY). 2017 Jan 5;9(1):68-97. doi: 10.18632/aging.101114.

27.

The role of the microbiome in kidney stone formation.

Mehta M, Goldfarb DS, Nazzal L.

Int J Surg. 2016 Dec;36(Pt D):607-612. doi: 10.1016/j.ijsu.2016.11.024. Epub 2016 Nov 12. Review.

28.

Does Vitamin D Supplementation Cause Kidney Stones?

Goldfarb DS.

J Urol. 2017 Feb;197(2):280-281. doi: 10.1016/j.juro.2016.11.072. Epub 2016 Nov 11. No abstract available.

PMID:
27845148
29.

Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.

Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC; Consensus Conference Group.

J Nephrol. 2016 Dec;29(6):715-734. Epub 2016 Jul 25. Review.

30.

The Role of the 24-Hour Urine Collection in the Prevention of Kidney Stone Recurrence.

Hsi RS, Sanford T, Goldfarb DS, Stoller ML.

J Urol. 2017 Apr;197(4):1084-1089. doi: 10.1016/j.juro.2016.10.052. Epub 2016 Oct 13. Review.

31.

l-Cystine Diamides as l-Cystine Crystallization Inhibitors for Cystinuria.

Hu L, Yang Y, Aloysius H, Albanyan H, Yang M, Liang JJ, Yu A, Shtukenberg A, Poloni LN, Kholodovych V, Tischfield JA, Goldfarb DS, Ward MD, Sahota A.

J Med Chem. 2016 Aug 11;59(15):7293-8. doi: 10.1021/acs.jmedchem.6b00647. Epub 2016 Jul 26.

32.

A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.

Laskowski LK, Goldfarb DS, Howland MA, Kavcsak K, Lugassy DM, Smith SW.

J Med Toxicol. 2016 Sep;12(3):305-8. doi: 10.1007/s13181-016-0543-y. Epub 2016 Mar 17.

33.

Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients?

St-Jules DE, Goldfarb DS, Sevick MA.

J Ren Nutr. 2016 Sep;26(5):282-7. doi: 10.1053/j.jrn.2016.02.005. Epub 2016 Mar 12. Review. Erratum in: J Ren Nutr. 2016 Nov;26(6):416.

34.

Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health.

Scales CD Jr, Tasian GE, Schwaderer AL, Goldfarb DS, Star RA, Kirkali Z.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1305-12. doi: 10.2215/CJN.13251215. Epub 2016 Mar 10. Review.

35.

The Clinical Impact of Accurate Cystine Calculi Characterization Using Dual-Energy Computed Tomography.

Haley WE, Ibrahim el-SH, Qu M, Cernigliaro JG, Goldfarb DS, McCollough CH.

Case Rep Radiol. 2015;2015:801021. doi: 10.1155/2015/801021. Epub 2015 Nov 25.

36.

The exposome for kidney stones.

Goldfarb DS.

Urolithiasis. 2016 Feb;44(1):3-7. doi: 10.1007/s00240-015-0847-4. Epub 2015 Nov 28. Review.

37.

Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis.

Song Y, Hernandez N, Shoag J, Goldfarb DS, Eisner BH.

Urolithiasis. 2016 Apr;44(2):145-8. doi: 10.1007/s00240-015-0819-8. Epub 2015 Nov 18.

PMID:
26582172
38.

Hypothesis: Urbanization and exposure to urban heat islands contribute to increasing prevalence of kidney stones.

Goldfarb DS, Hirsch J.

Med Hypotheses. 2015 Dec;85(6):953-7. doi: 10.1016/j.mehy.2015.09.003. Epub 2015 Sep 5.

39.

The Presence of Oxalobacter formigenes in the Microbiome of Healthy Young Adults.

Barnett C, Nazzal L, Goldfarb DS, Blaser MJ.

J Urol. 2016 Feb;195(2):499-506. doi: 10.1016/j.juro.2015.08.070. Epub 2015 Aug 17.

40.

Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment.

Nobel YR, Cox LM, Kirigin FF, Bokulich NA, Yamanishi S, Teitler I, Chung J, Sohn J, Barber CM, Goldfarb DS, Raju K, Abubucker S, Zhou Y, Ruiz VE, Li H, Mitreva M, Alekseyenko AV, Weinstock GM, Sodergren E, Blaser MJ.

Nat Commun. 2015 Jun 30;6:7486. doi: 10.1038/ncomms8486.

41.

The new epidemiology of nephrolithiasis.

Shoag J, Tasian GE, Goldfarb DS, Eisner BH.

Adv Chronic Kidney Dis. 2015 Jul;22(4):273-8. doi: 10.1053/j.ackd.2015.04.004. Review.

PMID:
26088071
42.

Urine proteomic analysis in cystinuric children with renal stones.

Kovacevic L, Lu H, Goldfarb DS, Lakshmanan Y, Caruso JA.

J Pediatr Urol. 2015 Aug;11(4):217.e1-6. doi: 10.1016/j.jpurol.2015.04.020. Epub 2015 May 29.

43.

Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases.

Lee MH, Sahota A, Ward MD, Goldfarb DS.

Curr Rheumatol Rep. 2015 May;17(5):33. doi: 10.1007/s11926-015-0510-7. Review.

44.

Helicobacter pylori, Oxalobacter formigenes, and risk of kidney stones.

Goldfarb DS.

Med Hypotheses. 2015 Jun;84(6):601. doi: 10.1016/j.mehy.2015.03.005. Epub 2015 Mar 6. No abstract available.

PMID:
25792104
45.

Enteric hyperoxaluria: an important cause of end-stage kidney disease.

Nazzal L, Puri S, Goldfarb DS.

Nephrol Dial Transplant. 2016 Mar;31(3):375-82. doi: 10.1093/ndt/gfv005. Epub 2015 Feb 20. Review.

46.

Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Decker BS, Goldfarb DS, Dargan PI, Friesen M, Gosselin S, Hoffman RS, Lavergne V, Nolin TD, Ghannoum M; EXTRIP Workgroup.

Clin J Am Soc Nephrol. 2015 May 7;10(5):875-87. doi: 10.2215/CJN.10021014. Epub 2015 Jan 12. Review.

47.

Production of stable isotope-labeled acyl-coenzyme A thioesters by yeast stable isotope labeling by essential nutrients in cell culture.

Snyder NW, Tombline G, Worth AJ, Parry RC, Silvers JA, Gillespie KP, Basu SS, Millen J, Goldfarb DS, Blair IA.

Anal Biochem. 2015 Apr 1;474:59-65. doi: 10.1016/j.ab.2014.12.014. Epub 2015 Jan 6.

48.

Dysphoria induced in dialysis providers by secondary hyperparathyroidism.

Soomro IH, Goldfarb DS.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):9-11. doi: 10.2215/CJN.11551114. Epub 2014 Dec 16. No abstract available.

49.

Novel cystine ester mimics for the treatment of cystinuria-induced urolithiasis in a knockout mouse model.

Sahota A, Parihar JS, Capaccione KM, Yang M, Noll K, Gordon D, Reimer D, Yang I, Buckley BT, Polunas M, Reuhl KR, Lewis MR, Ward MD, Goldfarb DS, Tischfield JA.

Urology. 2014 Nov;84(5):1249.e9-15. doi: 10.1016/j.urology.2014.07.043. Epub 2014 Oct 24.

50.

Cystine nephrolithiasis.

Fattah H, Hambaroush Y, Goldfarb DS.

Transl Androl Urol. 2014 Sep 1;3(3):228-233.

Supplemental Content

Loading ...
Support Center